



NEWS RELEASE

# Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET

4/26/2017

HOLON, Israel, April 26, 2017 /PRNewswire/ --

Compugen Ltd. (NASDAQ: **CGEN**), a therapeutic discovery company, announced today that the Company will host a live conference call on Tuesday, May 9, 2017 at 10:00 AM ET to review first quarter 2017 results. Compugen participants on the conference call will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and Chief Executive Officer; and Ari Krashin, Chief Financial and Operating Officer. The quarterly results will be released on the Company's website (<http://www.cgen.com>) prior to the call.

To access the live conference call by telephone, please dial 1-888-281-1167 from the US, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located at the following [link](#). Following the live audio webcast, a replay will be available on the Company's website through June 9, 2017.

## About Compugen

Compugen is a leading therapeutic discovery company whose mission is to utilize its broadly applicable predictive discovery infrastructure to discover novel drug targets and develop first-in-class therapeutics. Our current pipeline consists of early and preclinical stage immuno-oncology programs based on novel drug targets discovered internally, primarily immune checkpoint and myeloid protein target candidates. These programs focus on the development of first-in-class cancer immunotherapy drugs with the potential to harness the immune system to provide treatment solutions in areas of unmet medical need in various cancer types and patient populations, both as monotherapy and in combination with other drugs. In addition, our pipeline currently includes a preclinical

fusion protein autoimmune product candidate. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and related drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, therapeutic monoclonal antibodies are discovered and developed against the Company's novel drug target candidates.

For additional information, please visit Compugen's corporate website at <http://www.cgen.com>.

**Company contact:**

Susanna Chau

Director, Investor Relations and Corporate Communications

Compugen

Email: **[email protected]**

Tel: +1 (650) 263-7001

SOURCE Compugen Ltd.